Amgen (BUE:AMGN) Land And Improvements : ARS0 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Amgen Land And Improvements?

Amgen's land and improvements for the quarter that ended in Mar. 2024 was ARS0 Mil.

Amgen's quarterly land and improvements increased from Sep. 2023 (ARS0 Mil) to Dec. 2023 (ARS122,379 Mil) but then declined from Dec. 2023 (ARS122,379 Mil) to Mar. 2024 (ARS0 Mil).

Amgen's annual land and improvements increased from Dec. 2021 (ARS28,176 Mil) to Dec. 2022 (ARS48,954 Mil) and increased from Dec. 2022 (ARS48,954 Mil) to Dec. 2023 (ARS122,379 Mil).

Amgen Land And Improvements Historical Data

The historical data trend for Amgen's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Land And Improvements Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

15,720.46

21,077.42

28,176.21

48,953.80

122,379.00

Amgen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	122,379.00	-

Amgen Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.